Presented at PVRI 2026 Congress by Jim White, University of Rochester

Presented at PVRI 2026 Congress by Megan Griffiths, University of Texas Southwestern

Presented at PVRI 2026 Congress by Gisli Jenkins, Imperial College London

Presented at PVRI 2026 Congress by Namita Sood, University of California & Luke Howard, Imperial College London

Presented at PVRI 2026 Congress by Sandeep Sahay, Houston Methodist Hospital, and Meredith Broderick, United Therapeutics 

Presented at PVRI 2026 Congress by Franz Rischard, University of Arizona

Presented at PVRI 2026 Congress by Kari Gillmeyer, Boston University & Sarah Cohen, The Ohio State University & Nationwide Children's Hospital

Presented at PVRI 2026 Congress by Mark Toshner, University of Cambridge

Presented at PVRI 2026 Congress by Karen Osborn, Gil Golden, Sidra Hoffman, Luke Howard, Sandeep Sahay

Pulmonary arterial hypertension (PAH) is characterized by pulmonary vasoconstriction and vascular remodeling, leading to increased pulmonary vascular resistance, pathological right ventricular (RV) remodeling, and ultimately right heart failure and death.